NEW YORK (GenomeWeb News) – Pharmacogenomics firm AssureRx Health announced on Wednesday it has closed its Series C financing, raising $12.5 million.

The funding will go toward commercialization of its GeneSightRx Psychotropic and GeneSightRx ADHD tests as well as the development of new tests, the Mason, Ohio-based company said. AssureRx President and CEO James Burns added that the proceeds will be used to expand sales coverage, sponsor multiple clinical studies, and develop new products "to help accelerate our leadership position in psychiatric personalized medicine."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.